Okuninzi kwe-Ozempic kuthetha ukulawula ngcono uhlobo lwe-2 yeswekile

A BAMBA isiKhululo sasimahla 8 | eTurboNews | eTN
IAvatar kaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Novo Nordisk namhlanje ibhengeze ukuba i-US Food and Drug Administration (i-FDA) ivume i-2 mg ye-injection ye-Ozempic® (semaglutide), i-analog ye-glucagon-like peptide-1 (GLP-1) ye-analog eboniswe kunye nokutya kunye nokuzilolonga. ukuphucula iswekile yegazi kubantu abadala abanesifo sikashukela sohlobo lwe-2 kunye nokunciphisa umngcipheko weziganeko ezinkulu ze-cardiovascular ezifana nesifo senhliziyo, ukubetha okanye ukufa kwabantu abadala abanesifo seswekile se-2 kunye nesifo senhliziyo esaziwayo. nceda abantu banciphise ubunzima. I-Ozempic® iya kufumaneka kwiidosi ezintathu zonyango (2 mg, 0.5 mg, kunye ne-1 mg) ukunceda abantu abanesifo sikashukela sohlobo lwe-2 bafikelele kwiinjongo zabo zeswekile (A2C), ngoku kuquka abo bane-A1C ephezulu abangakwaziyo ukuhlangabezana nabo. Ithagethi ye-A1C.

Kwinkqubo ye-Ozempic® SUSTAIN isigaba se-3 yesilingo sekliniki, ukuya kwi-73% yabantu abanesifo sikashukela sohlobo lwe-2 abaphathwa nge-Ozempic® 1 mg banciphisa ishukela legazi kwaye bafikelela kwithagethi ye-American Diabetes Association <7%.3-5 Nangona kunjalo, kukho basengabantu abangekho kwithagethi yeswekile yegazi.1,4-10 Ozempic® 2 mg inceda abo bafuna ulawulo olongezelelweyo lwe-glycemic kwaye lukhetho olubalulekileyo kwizigulane kunye nababoneleli kunyango oluqhubekayo lwe-2 yeswekile.

"Uhlobo lwesifo sikashukela se-2 sisifo esiyinkimbinkimbi esinokuqhubela phambili ixesha elide nangona umntu elawula ngamayeza, ukutya kunye nokuzivocavoca," kusho uDkt Juan Pablo Frias, umlawuli wezonyango we-Velocity Clinical Research, eLos Angeles kunye nomphenyi oyintloko we-SUSTAIN FORTE, isigaba sesi-3 solingo lwezonyango oluxhasa imvume ye-Ozempic® 2 mg. "Ngokhuseleko oluqinisekisiweyo kunye nokusebenza kakuhle, i-Ozempic® inceda ekulawuleni i-glucose yegazi kwaye inikezela ngokunciphisa umngcipheko we-cardiovascular ngozi kubantu abadala abanesifo seswekile se-2 kunye nesifo senhliziyo esaziwayo, kunye nokunceda izigulane ezininzi zilahlekelwe isisindo. Ngedosi ye-2 mg, sinenketho eyongezelelweyo ukuze izigulana zihlale kunyango olufanayo nokuba iswekile yegazi ifuna ukutshintsha.

Kwilingo le-SUSTAIN FORTE, abantu abanomndilili oqala i-A1C ye-8.9% baphathwa nge-Ozempic® 2 mg bazuze ukuncipha okuphawulekayo kwezibalo kunye nokuphezulu kweshukela legazi le-2.1% ngeveki ye-40 xa kuthelekiswa ne-1.9% kunye ne-Ozempic® 1 mg (P<0.01 .1 Kuphononongo olufanayo, abantu abanobunzima bokuqala be-219 lb baphathwa nge-Ozempic® 2 mg bafumana ukwehla kobunzima be-14.1 lb xa kuthelekiswa nokuncipha kwesisindo se-12.5 lb kunye ne-Ozempic® 1 mg; umahluko wawungabalulekanga ngokwezibalo. Kuwo omabini amadosi e-Ozempic®, akukho miqondiso mitsha yokhuseleko ichongiwe.1 Ezona ziganeko zixhaphakileyo zixhaphakileyo sisisulelo.1 Izigulo ezingalunganga zesisu zenzeke rhoqo kwizigulana ezifumana i-Ozempic® 2 mg (34.0%) vs Ozempic® 1 mg (30.8% ).1

"I-Ozempic® ikwindawo yokunceda i-Novo Nordisk iqhube utshintsho kwi-diabetes, kunye nabantu abangaphezu kwesigidi abanesifo seswekile e-United States baphathwa nge-Ozempic®," kusho uDoug Langa, usekela-mongameli ophetheyo, eNyakatho Melika imisebenzi kunye nomongameli. yeNovo Nordisk Inc.  

I-Novo Nordisk ilindele ukusungula i-Ozempic® 2 mg e-United States kungekudala. I-Ozempic® 2 mg yamkelwa yi-Swiss Medic ngoSeptemba ka-2021 ilandelwa yi-Health Canada kunye ne-European Medicines Agency ngoJanuwari 2022.

Malunga nombhali

IAvatar kaLinda Hohnholz

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...